Heartflow Inc. is feeling the love of investors again as it closed a $215 series F financing round led by Bain Capital Life Sciences. The round marks a return to the equity markets after several years away; the company closed its series E in 2017 and a $65 million venture round in 2019. In early 2022, Heartflow scrapped its plans to go public through a special purchase acquisition company (SPAC) merger with Longview Acquisition, citing what both companies called “current unfavorable market conditions.” Longview had offered $690 million in July 2021, in a deal that implied an enterprise value of $2.4 billion at the time.
Following the termination of a planned merger with SPAC Medtech Acquisition Corp., Tel Aviv-based Memic Innovative Surgery Ltd. is looking to slowly roll out its Hominis surgical platform. Nasdaq-listed SPAC Medtech and Memic called off the agreement due to “market volatility and world events.”
Memic Innovative Surgery Ltd. agreed to combine with Medtech Acquisition Corp. in a transaction expected to close in the fourth quarter of 2021. The deal establishes an eye-popping $1 billion pro forma valuation for the company, which received FDA clearance for its first device just four months ago.
Memic Innovative Surgery Ltd. secured a major cash infusion to bring its freshly FDA-authorized Hominis robotic-assisted surgical platform to market. Peregrine Ventures and Ceros led the $96 million series D financing round with participation from Ourcrowd and Accelmed.
